AmCham NZ Profiles OptiRTP as MedTech Export Case Study
The American Chamber of Commerce in New Zealand (AmCham) has published a feature on OptiRTP, profiling the company’s Optimum Bio Sound Therapy (OBST) platform as an example of New Zealand medical technology expanding into international markets.
The article, written by AmCham Executive Director Mike Hearn, details the platform’s FDA Class I and Medsafe registrations and its adoption by high-performance coaches and athletes including Sir Graham Henry KNZM, Grant Sharman MNZM, Sarah Hirini MNZM, and Paralympic canoe sprinter Corbin Hart.
The AmCham feature also references OptiRTP’s upcoming Real-World Data study, developed with U.S.-based partner Lindus Health, which will evaluate OBST across five areas using validated PROMIS measures: pain interference, fatigue, sleep quality, physical function, and emotional well-being.
About OptiRTP
OptiRTP is a New Zealand health-technology company developing Optimum Bio Sound Therapy (OBST), a neuromodulation platform registered as an FDA Class I medical device. The platform has delivered over 200,000 therapy hours to more than 1,100 users. www.optirtp.com
